

1 The Missense of Smell: Functional Variability in the Human Odorant
2 Receptor Repertoire

3

4 Joel D. Mainland^{1,2,3,*}, Andreas Keller⁴, Yun R. Li^{2,5}, Ting Zhou², Casey Trimmer¹,
5 Lindsey L. Snyder¹, Andrew H. Moberly^{1,3}, Kaylin A. Adipietro², Wen Ling L. Liu²,
6 Hanyi Zhuang^{2,6}, Senmiao Zhan², Somin S. Lee^{2,7}, Abigail Lin², Hiroaki
7 Matsunami^{2,8}

8

9 ¹Monell Chemical Senses Center, 3500 Market Street, Philadelphia, PA 19104, USA

10 ²Department of Molecular Genetics and Microbiology, Duke University Medical
11 Center, Research Drive, Durham NC 27710, USA

12 ³Department of Neuroscience, University of Pennsylvania School of Medicine,
13 Philadelphia, Pennsylvania 19104

14 ⁴Laboratory of Neurogenetics and Behavior, The Rockefeller University, 1230 York
15 Avenue, New York, NY 10065, USA

16 ⁵Present address: University of Pennsylvania School of Medicine, 3450 Hamilton
17 Walk, 100 Stemmler Hall, Philadelphia, PA 19107, USA

18 ⁶Present address: Department of Pathophysiology, Key Laboratory of Cell
19 Differentiation and Apoptosis of National Ministry of Education, Shanghai Jiao
20 Tong University School of Medicine, Shanghai 200025, P. R. China.

21 ⁷Present address: Department of Ecology and Evolutionary Biology, Osborn
22 Memorial Labs, Yale University, 165 Prospect Street, New Haven, CT 06520-8106

23 ⁸Department of Neurobiology and Duke Institute for Brain Sciences, Duke
24 University Medical Center, Research Drive, Durham NC 27710, USA

25 *Corresponding author

26

27 **Humans have approximately 400 intact odorant receptors, but each individual**
28 **has a unique set of genetic variations that lead to variation in olfactory perception.**
29 **We used a heterologous assay to determine how often genetic polymorphisms in**
30 **odorant receptors alter receptor function. We identified agonists for 18 odorant**
31 **receptors and found that 63% of the odorant receptors we examined had**
32 **polymorphisms that altered *in vitro* function. On average, two individuals differ**
33 **functionally at over 30% of their odorant receptor alleles. To show that these *in***
34 ***vitro* results are relevant to olfactory perception, we verified that variations in**
35 ***OR10G4* genotype explain over 15% of the observed variation in perceived**
36 **intensity and over 10% of the observed variation in perceived valence for the high**
37 **affinity *in vitro* agonist guaiacol, but do not explain phenotypic variation for the**
38 **lower affinity agonists vanillin and ethyl vanillin.**

39 The human genome contains approximately 800 odorant receptor genes that have been
40 shown to exhibit high genetic variability¹⁻³. In addition, humans exhibit considerable
41 variation in the perception of odorants^{4,5} and variation in an odorant receptor predicts
42 perception in four cases: loss of function in *OR11H7P*, *OR2J3*, *OR5A1*, and *OR7D4*
43 leads to elevated detection thresholds for the respective agonists isovaleric acid⁶, cis-3-
44 hexen-1-ol⁷, β -ionone⁸, and androstenone⁹. These results suggest that although the
45 olfactory system uses a combinatorial code where multiple receptors encode a given
46 odorant, a single receptor can have a large influence on the perception of an odorant.

47 Understanding the role of a single receptor requires functional data for
48 receptor/odorant pairs. Matching mammalian odorant receptors to ligands has seen
49 limited success, and the picture is even worse when considering human odorant
50 receptors; ligands have been published for only 22 of the approximately 400 intact
51 human odorant receptors^{6,8-17}. This lack of data is a critical bottleneck in the field;
52 matching ligands to odorant receptors is essential for understanding the olfactory system
53 at all levels and is building viable models of olfaction.

54 Using a high-throughput system for functional testing of odorant receptors¹⁸, we can
55 now elucidate the role of missense single nucleotide polymorphisms in odorant receptor
56 function. Here we identify ligands for several orphan odorant receptors, determine the
57 prevalence and functional consequences of missense mutations in odorant receptors,
58 and measure the effect of these functional changes on human olfactory perception.

59 **Results**

60 **High-throughput screening of human odorant receptors**

61 To identify agonists for a variety of odorant receptors, we cloned a library of 511
62 human odorant receptors for a high-throughput heterologous screen. These clones

63 represent 394 (94%) of the 418 intact odorant receptor genes, and 428,793 (47%) of
64 their 912,912 intact odorant receptor alleles present in the 1000 Genomes Project. Some
65 odorant receptors were represented by multiple nonsynonymous alleles in the screen.

66 We screened the odorant receptor library with a panel of 73 odorants that have been
67 used in previous psychophysical testing^{9, 19} and used a cyclic adenosine
68 monophosphate (cAMP)-mediated luciferase assay to measure receptor activity²⁰
69 (Supplementary Fig. 1). In the primary screen we stimulated at a concentration of 100
70 μ M. We selected 1572 odorant/receptor pairs from this primary screen for a secondary
71 screen in which each odorant receptor was tested against a no-odor control as well as 1,
72 10 and 100 μ M concentrations of the odorant in triplicate. For 425 odorant/receptor
73 pairs, at least one concentration of the odorant produced significantly higher activation
74 than the no-odor control. These odorant/receptor pairs included 190 clones representing
75 160 unique odorant receptors.

76 We then constructed dose-response curves for at least one putative agonist of 160
77 odorant receptors. 27 odorant receptors showed a significant response to at least one
78 agonist, including nine that have previously been shown to respond to at least one
79 agonist in the published literature^{9, 16, 17} (Fig. 1). For the other 18 odorant receptors we
80 identified new agonists. This nearly doubles the total number of published human
81 odorant receptors with known agonists, bringing the total to 40^{6, 8-17}. The receptors
82 identified by this method are spread throughout 9 of the 13 gene families of odorant
83 receptors²¹ (Fig. 2), suggesting that our assay is useful for examining ligand-receptor
84 interactions across a wide variety of odorant receptors.

85 **Genetic variation in odorant receptors**

86 We identified agonists for seven odorant receptors that segregate between intact and
87 disrupted forms (Table 1), bringing the total number of segregating pseudogenes with

88 known agonists to eight⁶. Combined with psychophysics in a genotyped population,
89 these odorant receptor-agonist pairs can be used to probe the role of a single odorant
90 receptor in olfactory perception.

91 In addition to segregating pseudogenes and missense variation in conserved amino
92 acid residues, a segregating missense variation that alters non-conserved amino acid
93 residues of odorant receptors can also account for a portion of the variance in odor
94 perception⁷⁻⁹. How many of the odorant receptors with intact open reading frames have
95 functionally different variants, adding to the already considerable amount of variation in
96 the human odorant receptor repertoire? We found a median of 5 alleles with a minor
97 allele frequency (MAF) greater than 1% across 418 odorant receptors in the 1000
98 Genomes Project. 18 odorant receptors had only one allele with an MAF over 1% across
99 the 2184 haplotypes. In contrast, *OR51A2* had 19 different variants with an MAF over
100 1%. The odorant receptors for which we identified agonists did not exhibit a significantly
101 different number of polymorphisms than odorant receptors without identified agonists
102 (median alleles = 5 for both sets, Mann-Whitney U-test, $Z = 0.77$, $p = 0.44$, 2-sided).

103 To test how variability in amino acid sequence affected odorant receptor activation
104 by odorants, we targeted odorant receptors with at least one known agonist and cloned
105 alleles from pooled genomic DNA with the goal of representing the majority of protein-
106 coding alleles seen in the 1000 Genomes Project. For 16 odorant receptors we
107 successfully cloned 51 alleles, representing an average of 27,118 (77%) of their 34,944
108 alleles present in the 1000 Genomes Project. One mechanism through which genetic
109 polymorphisms could influence receptor function is by altering cell-surface expression.
110 We assessed the cell surface expression of these 51 cloned alleles using live-cell
111 immunostaining against the N-terminal Rho tag followed by Fluorescent Activated Cell
112 Sorting (FACS). Relative surface expression among each set of variants does not
113 correlate with either relative potency (Spearman $\rho=0.04$, $p=0.82$, Supplementary Fig.

114 2a) or relative efficacy (Spearman $\rho=0.13$, $p=0.45$, Supplementary Fig. 2b) of the
115 variants in the functional assay. While a complete lack of surface expression eliminates
116 receptor responses to known agonists, a high level of surface expression does not
117 reliably confer additional sensitivity. A small amount of cell surface expression is
118 sufficient to confer functional responses. In summary, FACS does not provide enough
119 resolution to determine if functional variation is due to cell-surface expression defects.

120 **Functional consequences of genetic variation**

121 We screened 46 of the alleles used in the FACS analysis against 55 odorants
122 chosen quantitatively to span the physicochemical space¹⁷ (Supplementary Fig. 3).
123 Across odorants the absolute magnitudes of response varied, but the relative responses
124 of variant alleles remained consistent (Fig. 3a,b, Supplementary Fig. 4). In other words,
125 if a variant is hypersensitive to one agonist, that variant tends to be hypersensitive to all
126 agonists. We found no case of a genetic change that resulted in a change in odor tuning
127 (Supplementary Fig. 4), but our odorant library design was chosen to span odorant
128 space and was therefore not ideal for identifying more subtle changes.

129 We then examined how the variant allele responses compared across a range of
130 concentrations by constructing a dose response curve from 10 nM to 10 mM (Fig. 3c,
131 Supplementary Fig. 5). Here, we included the 15 odorant receptors tested against all 55
132 odorants as well as 12 additional odorant receptors. We typically used only a single
133 agonist, as our results from using a broad set of odorants suggested that the differences
134 between alleles using one odorant were highly correlated to differences between alleles
135 using different odorants. We fit the data to a sigmoid curve and compared the variant
136 alleles using an extra sums-of-squares test. A pair of alleles was classified as
137 hyper/hypofunctional if one allele in the pair had both a lower potency (EC50) and a
138 lower efficacy (maximum value). Comparing one allele to all other alleles of the same

139 odorant receptor from the 1000 Genomes Project revealed that 11% of the alleles were
140 hyperfunctional, 68% were indistinguishable and 6.8% were hypofunctional. 7.9% of the
141 alleles were pseudogenes and for 5.5% of the alleles potency and efficacy did not
142 change concordantly, so we could not clearly classify them as hypo or hyperfunctional
143 (Fig. 4a). 63% (17/27) of the odorant receptors we examined had polymorphisms that
144 altered *in vitro* function. Residues that are polymorphic across alleles with measured
145 function are shown in Figure 4b. There is no obvious pattern to the amino acids that
146 change function; they are found all over the protein. The odds that a residue altered
147 function in our assay did not correlate with evolutionary conservation (GERP score, $r = -$
148 0.04, $p = 0.83$), predictions from SIFT ($r = 0.05$, $p = 0.80$), or predictions from PolyPhen
149 ($r = -0.05$, $p = 0.81$).

150 To quantify functional differences across the 1000 Genomes Project population we
151 assigned *in vitro* results to each participant according to their allele type. We had *in vitro*
152 results for 46,561 (79%) of the 58,968 alleles (27 odorant receptors x 1092 subjects x 2
153 alleles). When we conservatively classified all pairwise comparisons including those
154 involving untested alleles as functionally identical, we saw an average of 16 functional
155 differences in dose response out of 54 possible functional differences (27 odorant
156 receptors tested in dose-response x 2 alleles, Fig. 5a, histogram). When we classified all
157 pairwise comparisons including an untested allele as functionally different, we saw an
158 average of 22 functional differences in dose response out of 54 possible functional
159 differences. These results were consistent if we excluded the 500 related participants.
160 In other words, two individuals differ functionally at over 30% (16/54) of their odorant
161 receptor alleles. Pairs where both participants had Asian ancestry (CHB, CHS, and
162 JPT) were more functionally similar than pairs where neither participant had Asian
163 ancestry (median Asian = 13; median non-Asian = 17; Mann-Whitney U-test, $z=127$, $p <$
164 0.0001, 2-sided). Pairs where both participants had African ancestry (ASW, LWK, and

165 YRI) were more functionally different than pairs where neither participant had African
166 ancestry (median African = 16; median non-African = 15; Mann-Whitney U-test, $z=29$ $p <$
167 0.0001 , 2-sided)²², in line with those populations having a greater genetic diversity (Fig.
168 5b). However, when taking genetic diversity into account, pairs where both participants
169 had African ancestry (ASW, LWK, and YRI) were more functionally similar than pairs
170 where neither participant had African ancestry (median African = -0.83 ; median non-
171 African = 0.36 ; Mann-Whitney U-test, $z=149$, $p < 0.0001$, 2-sided) (Fig. 5c). This shows
172 that, although there is greater genetic variability among Africans, much of this diversity
173 does not translate into functional differences relative to other groups.

174 **Perceptual consequences of genetic variation**

175 We have so far shown that genetic changes are widespread in the human population
176 and that these genetic changes result in widespread *in vitro* functional changes. We next
177 set out to determine if the observed *in vitro* functional changes lead to the predicted
178 perceptual consequences. We selected an odorant receptor, *OR10G4*, for further
179 testing because we had genomic DNA of subjects that had been tested for their
180 perception of three *OR10G4* agonists¹⁹, and because functional and non-functional
181 *OR10G4* alleles were common in the 1000 Genomes Project²². We successfully
182 obtained *OR10G4* sequences from 308 of the 391 participants who had rated their
183 perceived intensity and valence for guaiacol, vanillin, and ethyl vanillin. We then
184 examined the effect of each *OR10G4* allele on the perceptual phenotypes (Fig. 6).

185 There were four *OR10G4* alleles with an MAF greater than 4% in the participant
186 population: the reference allele (ALTYMGVPRK), and three variant alleles that differ
187 from the reference allele by two (APTYMGPERK), five (VLTYVGPEGQ), or eight
188 (ALICVSSEGQ) amino acids. The APTYMGPERK allele was more sensitive to guaiacol
189 than the reference allele, but the effect was small ($\log EC_{50}$ ALTYMGVPRK = -7.4 , \log

190 EC50 APTYMGPERK = -7.7 , sum of squares test, $F(3,42) = 6.38$, $p < 0.002$). The
191 VLTYVGPEGQ allele had a much lower affinity to the three odorants than the reference
192 allele, but still showed significant responses ($\log EC50 = -5.5$, sum of squares test
193 against reference, $F(3,42) = 459$, $p < 0.001$; sum of squares test against vector control,
194 $F(3,42) = 149$, $p < 0.001$). The ALICVSSEGQ allele was not significantly different from
195 the control cells transfected with vector only (sum of squares test against vector control,
196 $F(3,42) = 2.2$, $p = 0.11$) (Fig. 6a). We generated odorant receptors with each of the
197 SNPs in a reference background and found that no single SNP accounted for the
198 functional impairment in the VLTYVGPEGQ and ALICVSSEGQ alleles, suggesting that
199 multiple residues interact to cause the decrease in affinity (Supplementary Fig. 6).

200 Multiple regression analysis was used to test if *OR10G4* allele-type significantly
201 predicted participants' perception of the three *in vitro* agonists. The predictors, allele
202 counts (0,1,or 2) for the four alleles with MAF > 4% in the participant population, were
203 regressed against the odor rating rank. *OR10G4* allele type predicted 15.4% of the
204 variance in perceived intensity of guaiacol ($r^2 = 0.165$, adjusted $r^2 = 0.154$, compared to
205 constant model, $F(4,303) = 15.0$, $p < 0.001$ after false discovery rate (FDR) correction).
206 The model estimated that subjects with none of the major alleles would rank the intensity
207 of guaiacol 24th relative to the other tested odors. Each copy of the ALTYMGPERK
208 allele is associated with an increase in perceived intensity (decreased rank) of guaiacol
209 by 2.1 ranks ($\beta = 2.10$, $p < 0.04$), and each copy of the VLTYVGPEGQ and
210 ALICVSSEGQ alleles is associated with a decrease in perceived intensity by 2.4 and 4.3
211 ranks respectively ($\beta = -2.39$, $p < 0.02$; $\beta = -4.34$, $p < 0.005$). The APTYMGPERK allele
212 was not significantly associated with the intensity rank ($\beta = 1.01$, $p = 0.32$).

213 In addition to intensity, *OR10G4* allele type predicted 10.3% of the variance in
214 perceived valence of guaiacol ($r^2 = 0.115$, adjusted $r^2 = 0.103$, compared to constant

215 model, $F(4,303) = 9.85$, $p < 0.001$ after false discovery rate (FDR) correction). The
216 model estimated that subjects with none of the major alleles would rank the valence of
217 guaiacol 29th relative to the other tested odors. Each copy of the VLTYVGPEGQ and
218 ALICVSSEGQ alleles is associated with an increase in perceived valence (increased
219 rank) of guaiacol by 3.3 and 3.7 ranks respectively ($\beta = 3.33$, $p < 0.002$; $\beta = 3.71$, $p <$
220 0.03), but the ALTYMGPVRK and APTYMGPERK alleles were not significantly
221 associated with the valence rank ($\beta = -0.69$, $p = 0.52$; $\beta = 1.88$, $p = 0.08$).

222 In contrast to guaiacol, neither perceived intensity nor valence of vanillin and ethyl
223 vanillin were predicted by *OR10G4* allele-type (vanillin intensity—compared to constant
224 model, $F(4,303) = 0.95$, uncorrected $p = 0.44$; ethyl vanillin intensity—compared to
225 constant model, $F(4,303) = 0.95$, uncorrected $p = 0.44$; vanillin valence—compared to
226 constant model, $F(4,303) = 0.84$, uncorrected $p = 0.50$; ethyl vanillin valence—compared
227 to constant model, $F(4,303) = 0.50$, uncorrected $p = 0.74$). As further controls, the 308
228 participants were also psychophysically tested for their intensity and valence perception
229 of 63 odors that are not known to be *OR10G4* agonists, as well as two solvents. Of the
230 68 compounds, only guaiacol intensity and valence were significantly correlated with
231 *OR10G4* allele type (Fig. 6c,d).

232 Discussion

233 Here we have identified 27 odorant receptors with known agonists that have
234 functionally different alleles that segregate in the human population and demonstrated
235 that this segregation is relevant to human odorant perception. This nearly doubles the
236 number of human odorant receptors with a known agonist, and is the first investigation of
237 the functional role of genetic variation in a large set of odorant receptors. Pairing
238 odors and odorant receptors and verifying the functional consequences of
239 segregating polymorphisms *in vitro* allows us to address previously inaccessible

240 questions regarding how activation of an individual odorant receptor alters olfactory
241 perception. This promises to be a rich future field of study, as we do not currently know
242 how the odorant receptor array codes for odor threshold, intensity, or character.
243 Understanding how the functional alteration of an odorant receptor affects the neural
244 code is a crucial first step in a model of olfactory perception.

245 Each pair of individuals had, on average, differences in 16-22 out of a possible 54
246 alleles (27 odorant receptor genes with dose-response data x 2 alleles per subject). If we
247 extrapolate to the approximately 400 intact odorant receptors, we would expect each
248 pair of individuals to differ at somewhere between 237–326 of the 800 alleles. This
249 suggests that odor detection at the peripheral level is highly variable. Variation at the
250 peripheral level leads to variability in odor perception across individuals in several cases;
251 in addition to the OR10G4/guaiacol association demonstrated here, four olfactory
252 perceptual phenotypes have previously been linked to a single odorant receptor genes⁶⁻⁹
253 and five additional olfactory phenotypes have been linked to regions of the genome
254 containing more than one receptor²³⁻²⁵. Each individual, therefore, has a highly
255 personalized set of olfactory receptors that affects his or her perception of odors.

256 We chose to focus only on SNPs in the coding regions of the odorant receptors due
257 to the lack of an efficient assay for testing the effects of noncoding polymorphisms on
258 expression. That said, there is considerable variation in noncoding regions, which can
259 lead to altered gene transcription²⁶ and even changes in sensory perception²⁷. Similarly,
260 we did not examine copy number variation, which is widespread in human odorant
261 receptors^{28, 29}. Thus, our data underestimate the potential extent of variation in each
262 individual's expressed odorant receptor repertoire.

263 Our study did not find any evidence suggesting SNPs that alter *in vitro* function are
264 restricted to a particular domain of the receptor, deviate from neutral evolution, or are
265 predicted by two popular computational algorithms. Note, however, that our study was

266 not designed to carefully detect changes due to a particular SNP; because we did not
267 generate every possible combination of SNPs for the majority of odorant receptors,
268 SNP-specific alterations may be confounded by linkage in the tested alleles.

269 Although we found that *OR10G4* has at least three *in vitro* agonists, the *OR10G4*
270 allele type only predicted perceived intensity and valence for guaiacol. The dose-
271 response curves in Figure 6a show that guaiacol is a more potent agonist than either
272 vanillin or ethyl vanillin. Although more data is needed, one possible interpretation is
273 that the intensity and valence of odorants that only weakly activate a receptor will not be
274 altered by functional variation in the receptor. Indeed, this is similar to the association
275 between *OR7D4* and androstenone⁹. In that case, both of the major alleles respond to
276 androstenone *in vitro*, but the WM allele is much less potent than the RT allele. As with
277 *OR7D4*, participants with the lower affinity *in vitro* allele find the odor to be less intense
278 and more pleasant. This suggests that not all functional variation *in vitro* will lead to
279 perceptual variation, but the exact rules determining how much of this variation is
280 compensated for at later stages of processing will require further investigation.

281 *OR10G4* explains 15.4% of the variance in guaiacol intensity, which is lower than the
282 39% of androstenone intensity variation explained by *OR7D4* genotype. The reason for
283 this lower explanatory value is unclear. One possibility is that more odorant receptors
284 play a role in the perception of guaiacol than in the perception of androstenone,
285 therefore reducing the influence of a single odorant receptor on the percept. Another is
286 that confounding variables, such as culture and genetic background may have
287 differential effects on the two phenotypes.

288 The role of a single odorant receptor in olfactory perception is currently unknown, in
289 part because of the large search space for both odorants and odorant receptors and the
290 redundant nature of the combinatorial code for odorant identity. By assigning ligands to
291 odorant receptors, measuring the functional consequences of segregating

292 polymorphisms *in vitro*, and linking *in vitro* function to human behavior, these data
293 provide a solid platform from which to probe the effects of a single odorant receptor on
294 olfactory perception.

295

296

297

298 **Acknowledgements**

299 This work was supported by R01 DC005782, R01 DC012095, R03 DC011373, R01
300 DC013339, and an NRSA postdoctoral fellowship F32 DC008932 to J.D.M. A portion of
301 the work was performed using the Monell Chemosensory Receptor Signaling Core and
302 Genotyping and DNA/RNA Analysis Core, which are supported, in part, by funding from
303 the NIH-NIDCD Core Grant P30 DC011735. The FACS analysis was performed using
304 the Duke Cancer Institute Flow Cytometry Core. The authors thank D. Marchuk for
305 sharing equipment, Leslie B. Vosshall for supervising the collection of psychophysical
306 data and DNA samples by A.K. in her laboratory, and R. Molday for 4D2 anti-rhodopsin
307 antibody.

308 **Author contributions**

309 J.D.M. and H.M. conceived and designed the project. J.D.M., C.T., A.H.M., L.L.S.,
310 S.Z., L.L., T.Z., Y.R.L., H.Z., S.L., A.L. and K.A.A. performed research. A.K. collected the
311 psychophysical data and provided DNA samples. J.D.M. carried out the analysis and
312 wrote the paper with help from all authors. H.M. supervised the project.

313

314

315

316

317

318 **Figure Legends**

319 Figure 1: Dose response curves of the most common functional allele for 27
320 receptors. Circles and solid lines represent the response of the odorant receptor to the
321 odorant in the title of each pane, X's and dotted lines represent the response of the
322 vector-transfected control to the odorant in the title of each pane. Error bars are
323 standard error. See Table S1 for odor abbreviations.

324

325 Figure 2: Unrooted tree based on similarity of amino acid properties. 27 odorant
326 receptors with agonists are highlighted in red, and represent 9 of the 13 odorant receptor
327 gene families. Grantham's amino acid property scales were used to quantify receptor
328 similarity³⁰ and distances were calculated using the unweighted pair group method with
329 arithmetic mean (UPGMA).

330

331 Figure 3: Functional testing of odorant receptor variants. (a) Sensitivity-ordered
332 tuning curves for 5 variant alleles of *OR2B11* tested against the 55 representative
333 odorants at 100 μ M. If a given odorant did not significantly activate any of the variant
334 receptors above the no-odor control (2-tailed t-test, $\alpha=0.05/55$), that odorant's response
335 was set to zero across all variants. Odorants were ordered along the x-axis according to
336 the response they elicited from the *OR2B11* reference allele (see Fig. S3 for odor
337 names). Error bars are standard error over three replicates. (b) The responses of the
338 four variant alleles to the 55 representative odorants at 100 μ M are plotted against the
339 *OR2B11* reference allele's responses. The black line represents the unit slope line. (c)
340 Dose response curves for the *OR2B11* alleles for three different odorants. Y-axis
341 represents the luciferase value normalized to the reference allele. Error bars are
342 standard error over three replicates.

343

344 Figure 4: Summary of functional variation. (a) The type of functional differences
345 among 27 odorant receptors of 1092 participants from the 1000 Genomes Project. Note
346 that pseudogenes account for a small portion of the variability relative to missense
347 variations. (b) Snake plot of a typical odorant receptor showing residues where SNPs
348 alter the function of the receptor. Amino acid residues that did not vary between any of
349 the minor alleles and their reference allele are shown in gray. The remaining residues
350 are colored according to the odds that they alter function given our current dose-
351 response data. Amino acid positions conserved in at least 90% of the receptors are
352 labeled with their single-letter amino acid code.

353

354 Figure 5: Functional differences between participants. The number of functional
355 differences (a), nucleotide differences (b), and z-scored functional differences minus z-
356 scored nucleotide differences (c) among 27 odorant receptors of 1092 participants from
357 the 1000 Genomes Project. The colors of the squares represent the number of
358 differences between participants. Participant populations are labeled on the axes and
359 separated by black grid lines. The histograms of the number of differences show the
360 color key used in the main figure. The legend displays ethnic groups from (a-c) at the
361 place of geographic origin; arrows point to the location of sample collection. ASW,
362 African ancestry in Southwest USA; CEU, Utah residents with Northern and Western
363 European ancestry from the CEPH collection; CHB, Han Chinese in Beijing; CHS, Han
364 Chinese South; CLM, Colombian in Medellin, Colombia; FIN, Finnish; GBR, British
365 individuals from England and Scotland; IBS, Iberian populations in Spain; JPT,
366 Japanese in Tokyo; LWK, Luhya in Webuya, Kenya; MXL, Mexican ancestry in Los
367 Angeles, California; PUR, Puerto Rican; TSI, Tuscanians in Italy; YRI, Yoruba in Ibadan,
368 Nigeria.

369

370 Figure 6: *OR10G4* allele effects on perceived intensity and valence. (a)
371 Concentration response curves of *OR10G4* alleles with a frequency greater than 4% in
372 the participant population. Error bars are standard errors of 3 replicates. Y-axis values
373 are normalized to the baseline response of the reference allele. (b) Perceived intensity
374 and valence rank for three *in vitro* *OR10G4* agonists by allele of *OR10G4*. Each
375 participant is represented twice—once for the maternal and once for the paternal allele.
376 The width of each violin is proportional to the number of participants assigning a given
377 rank. The black line inside the violin denotes the median rank. The amino acid changes
378 are relative to the hg19 reference sequence. The frequency listed is the allele frequency
379 in the 308 participants. All unlisted alleles occurred with a frequency lower than 4%.
380 Asterisks signify that the allele had a significant effect in the regression model, and are
381 only shown for regression models that were overall significantly different from a constant
382 model; one asterisk signifies $p < 0.05$, two asterisks signify $p < 0.01$. (c,d) Percentage of
383 perceptual variance (r^2) in intensity (c) and valence (d) ranking explained by *OR10G4*
384 allele types. Each odor was analyzed using the multiple linear regression model outlined
385 in the main text. Three asterisks signifies $p < 0.001$ after false-discovery rate (FDR)
386 correction. For all other odorants, $p > 0.05$ after FDR correction.

387

388 Table 1: Seven segregating pseudogenes with agonists. The frequency of the
389 disrupted allele in the 1000 Genomes Project²² is listed. In cases where the variant allele
390 alters a highly-conserved domain in the protein, the conserved amino acid that varies is
391 underscored.

392

Odorant receptor name	Frequency of pseudogene allele	Result	Agonist
<i>OR2B11</i>	43%	8 amino acid protein	Cinnamaldehyde
<i>OR4E2</i>	30%	<u>M</u> AYDRY domain	Amyl acetate
<i>OR8K3</i>	24%	MAYD <u>R</u> Y domain	(+)-Menthol
<i>OR10A6</i>	22%	PMLN <u>P</u> LIY domain	3-phenyl propyl propionate
<i>OR2C1</i>	4%	272 amino acid protein	Octanethiol
<i>OR4Q3</i>	1.50%	159 amino acid protein	Eugenol
<i>OR10G7</i>	1.40%	191 amino acid protein	Eugenol

393

Table 1

394

395 **METHODS**

396 **Cloning**

397 Odorant receptor open reading frames were amplified from the genomic DNA of 20
398 participants from the International Hapmap Consortium using Phusion polymerase and
399 subcloned into *pCI* expression vectors (Promega) containing the first 20 residues of
400 human rhodopsin (Rho tag). The sequences of the cloned receptors were verified by
401 sequencing (3100 Genetic Analyzer, Applied Biosystems).

402 **Fluorescence-activated Cell Sorter (FACS) Analysis**

403 We conducted FACS analysis on all tested clones for the 17 odorant receptors where we
404 had more than one clone (Supplementary Fig. 5). Hana3A cells were maintained in
405 minimal essential medium (Sigma) containing 10% fetal bovine serum (Sigma), 500 ug/ml
406 penicillin-streptomycin (Invitrogen) and 6 ug/ml amphotericin B (Sigma). Cells were
407 seeded in 35mm dishes (Falcon) and grown overnight at 37°C and 5% CO₂. The
408 following day, each dish was transfected using 4ul Lipofectamine 2000 (Invitrogen),
409 1200ng Rho-tagged odorant receptor, 300ng hRTP1S, and 20ng of EGFP to control for
410 transfection efficiency. 24-hours post-transfection, cells were washed with PBS and
411 detached from the dishes using Cellstripper (Cellgro). Primary incubation was carried out
412 at 4°C using mouse monoclonal antibody anti-rhodopsin 4D2³¹ (gift from R. Molday)
413 diluted 1:50 in PBS containing 2% FBS, and 15mM NaN₃ for 30 minutes. Cells were
414 washed in PBS/FBS/NaN₃, followed by secondary incubation with Phycoerythrin (PE)-
415 conjugated donkey anti-mouse antibody (Jackson Immunologicals) diluted 1:100 in
416 PBS/FBS/NaN₃ for 30 minutes covered with aluminum foil. Cells were washed and
417 resuspended in PBS/FBS/NaN₃ containing 1:500 dilution of 7-Aminoactinomycin D
418 (7AAD 1mg/ml; Calbiochem), a fluorescent, cell-impermeable DNA binding agent that

419 selectively stains dead cells. Fluorescent cell sorting was conducted using a BD
420 FACSCanto (BD Biosciences). Cells that were EGFP-negative and/or 7AAD-positive
421 were removed from further analysis. Cell-surface expression is quantified as PE
422 fluorescence intensity. Data collection and analysis were not randomized.

423 **Luciferase assay**

424 The Dual-Glo™ Luciferase Assay System (Promega) was used to measure receptor
425 responses as previously described²⁰. Hana3A cells were transfected with 5 ng/well of
426 RTP1S³², 5 ng/well of pRL-SV40, 10 ng/well of CRE-luciferase, 2.5 ng/well of M3³³, and
427 5 ng/well of odorant receptor. 1M odorant stocks are diluted in DMSO. 24 hours
428 following transfection, transfection media was removed and replaced with the
429 appropriate concentration of odor diluted from the 1M stocks in CD293 (Gibco). Four
430 hours following odor stimulation luminescence was measured using a Polarstar Optima
431 plate reader (BMG). All luminescence values were divided by the Renilla Luciferase
432 activity to control for transfection efficiency in a given well. Data were analyzed with
433 Microsoft Excel, GraphPad Prism 4, and MATLAB.

434 **1000 Genomes Project data**

435 Allele frequency in the human population was derived from the May 2011 phased
436 release of the 1000 Genomes Project public data ([ftp://ftp-
437 trace.ncbi.nih.gov/1000genomes/ftp/release/20110521/](ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/release/20110521/))²². Variant calls were obtained
438 from the public repository in vcf format using tabix³⁴. A custom-written MATLAB script
439 was used to translate the vcf file into 2184 full-length phased alleles (two alleles for each
440 of the 1092 participants in the public database).

441 **Human odorant receptor genotyping**

442 Venous blood (8.5 ml) was collected from participants and genomic DNA was
443 prepared with the Qiagen PAXgene blood DNA kit. For sequencing, human genomic
444 DNAs were amplified with HotStar Taq (Qiagen) with primers upstream (5'-
445 ACCTGGTTGATGCAGTTTCC-3') and downstream (5'-
446 AAACCTATTGATGAGAAATGAGTCAA-3') of the OR10G4 open reading frame. The
447 PCR products were then purified using Sephadryl S-400 (GE Healthcare) and
448 sequenced with a 3100 or 3730 Genetic Analyzer (ABI Biosystems).

449 **Procedures for olfactory psychophysics**

450 All psychophysical data was obtained from Keller et al. (2012)¹⁹ and approved by the
451 Rockefeller University Institutional Review Board. All subjects gave informed consent to
452 participate and were financially compensated for their time and effort. Exclusion criteria
453 for subjects were: allergies to odors or fragrances, a history of nasal illness, upper
454 respiratory infection, seasonal allergy, prior endoscopic surgery on the nose, pre-existing
455 medical condition that has caused a reduced sense of smell such as head injury, cancer
456 therapy, radiation to head and neck, or alcoholism. Pregnant women and children under
457 18 were excluded from this study. Of the 308 subjects (138 male), 133 were Caucasian,
458 29 were Asian, and 77 were African-American. The median age was 35 years, with a
459 range of 19 to 66. In brief, participants rated the intensity and valence of 66 odorants on
460 a 7-point scale. The intensity scale was labeled with 1 as “extremely weak” and 7 as
461 “extremely strong”. The valence scale was labeled with 1 as “extremely unpleasant” and
462 7 as “extremely pleasant”. Stimuli were presented in jars. For a detailed description of
463 the psychophysical methods, see Keller et al.⁹. Three of these odorants, ethyl vanillin,
464 vanillin and guaiacol, are *in vitro* agonists to *OR10G4*. We examined the ratings of the
465 higher of two tested concentrations. Ethyl vanillin and vanillin were presented at a 1/200

466 dilution in propylene glycol, guaiacol was presented at a 1/1,000,000 dilution in paraffin
467 oil. Our data collection and analysis was blind to genotype, as all sequencing was
468 conducted after phenotyping of the human subjects was complete. Data collection and
469 analysis were not randomized.

470 **Statistical analysis**

471 **Screening procedure**

472 We stimulated the entire odorant receptor library with 73 odorants used in previous
473 psychophysical testing⁹. We applied the odorants at 100 μ M (except for androstenone
474 and androstadienone, which were both applied at 10 μ M) and ranked odorant/receptor
475 pairs by their activity above the no odor condition. We selected the top 5% of
476 odorant/receptor pairs from this primary screen--some receptors were very promiscuous,
477 so we tested only the top ten ligands for a given receptor. We then performed a
478 secondary screen in which each odorant receptor was tested against a no-odor control
479 as well as 1, 10 and 100 μ M. Each comparison was performed in triplicate, where each
480 measure was collected from separate wells, but each well contains cells from the same
481 parent plate of cells. Statistical significance was assessed by 2-sided t-test comparing
482 the 3 wells stimulated with odor with the 3 wells stimulated with media alone. As this was
483 a screening procedure, the data distribution was assumed to be normal but this was not
484 formally tested. In addition, the tests were uncorrected for multiple comparisons. We
485 then constructed dose-response curves using concentrations ranging from 10 nM to 10
486 mM for the odor/receptor pairs that were significantly different from baseline in the
487 secondary screen. Each odorant receptor-odorant dose was tested in triplicate, where
488 each measure was collected from separate wells, but each well contains cells from the
489 same parent plate of cells, and a vector-only control was included for each odorant. We

490 fit the data to a sigmoidal curve. We counted an odorant as an agonist if the 95%
491 confidence intervals of the top and bottom parameters did not overlap, the standard
492 deviation of the fitted log EC50 was less than 1 log unit, and the extra sums-of-squares
493 test confirmed that the odorant activated the receptor significantly more than the control,
494 which was transfected with an empty vector. Data collection and analysis were not
495 randomized.

496 **Screening 55 odorants**

497 To choose 55 odorants that quantitatively span chemical space we generated 20
498 physicochemical descriptors that predict 62% of the variance in mammalian odorant
499 receptor responses¹⁷ for 2715 commonly used odorants. We then divided the 2715
500 odorants into 55 clusters using k-means clustering. For each cluster, we selected the
501 odorant closest to the centroid of the cluster among odorants that are previously shown
502 to activate at least one odorant receptor. If no such agonist was present in the cluster,
503 we selected the odorant closest to the centroid of the cluster to maximize structural
504 diversity. Each odorant was screened against each receptor variant at 100 μ M in
505 triplicate where each measure was collected from separate wells, but each well contains
506 cells from the same parent plate of cells. We performed an ANOVA on the responses
507 from the clones of each odorant receptor. We used 15 odorant receptors where we had
508 more than one allele cloned with an allele frequency greater than 1% in the 1092
509 participants and the cloned alleles represented a large percentage of the 2184 alleles.
510 For 13 odorant receptors, the cloned alleles represented more than 85% of the 2184
511 alleles. For *OR2B11* the cloned alleles represented 37.5% of the alleles and for *OR10G4*
512 the cloned alleles represented 29.5% of the alleles. Data collection and analysis were
513 not randomized.

514 **Dose response curves**

515 We tested odorant receptors with odorants ranging in concentration from 10 nM to 10
516 mM. All numerical results are reported as mean \pm s.e.m. and represent data from a
517 minimum of three replicates, where each measure was collected from separate wells,
518 but each well contains cells from the same parent plate of cells. We fit the resulting data
519 with a 3-parameter logistic model. We counted an odorant as an agonist if the 95%
520 confidence intervals of the top and bottom parameters did not overlap, the standard
521 deviation of the fitted log EC50 was less than 1 log unit, and the extra sums-of-squares
522 test confirmed that the odorant activated the receptor significantly more than the vector-
523 only transfected control.

524 For each pair of alleles, we determined if one model fit the data from both alleles
525 better than two separate models using the extra sums-of-squares test. A pair of alleles
526 was classified as hyper/hypofunctional if one allele in the pair had both a higher EC50
527 (lower efficacy) and a lower potency (dynamic range, or top-bottom). A pair of alleles
528 was designated as “unclassified” if the potency and efficacy showed discordant changes
529 (i.e. one allele was more sensitive, but had a lower efficacy).

530 To compare each pair of individuals, we took the four alleles from a single odorant
531 receptor and removed any pairs of alleles that were indistinguishable according to the
532 above criteria. Each remaining pair was counted as one functional difference. These
533 values were summed across odorant receptors, with a maximum of 48 possible
534 functional differences per pair of participants. Data collection and analysis were not
535 randomized.

536 **Odds that a SNP alters function**

537 We aligned the nucleotide sequences of the odorant receptor variants to a multiple
538 sequence alignment of 1425 intact mouse and human odorant receptors. For each SNP

539 we calculated the ratio of the odds that a functional change (as defined above, relative to
540 the most common functional variant) occurred in an allele with a non-synonymous amino
541 acid to the odds that a functional change occurred in an allele with a synonymous amino
542 acid. We used SNPnexus³⁵ (Ensembl 63 build) to generate GERP, SIFT, and Polyphen
543 scores.

544 **Multiple linear regression model**

545 Multiple regression analysis was used to test if the number of OR10G4 alleles
546 significantly predicted participants' perception of the three *in vitro* agonists. To
547 determine the minimum sample size for this analysis, we performed a Monte-Carlo
548 simulation using the data from Keller et al.⁹. We ranked each subject's ratings of the
549 odorants to control for differences in general olfactory acuity and usage for the rating
550 scale across subjects. The predictors were allele counts (0,1,or 2) for the four alleles
551 with MAF > 4% in the participant population. Data collection and analysis were not
552 randomized.

553

554 **References**

555

- 556 1. Menashe, I., Man, O., Lancet, D. & Gilad, Y. Different noses for different people.
557 *Nat. Genet.* **34**, 143-144 (2003).
- 558 2. Hasin-Brumshtein, Y., Lancet, D. & Olender, T. Human olfaction: from genomic
559 variation to phenotypic diversity. *Trends Genet.* **25**, 178-184 (2009).
- 560 3. Olender, T., *et al.* Personal receptor repertoires: olfaction as a model. *BMC*
561 *Genomics* **13**, 414 (2012).
- 562 4. Ayabe-Kanamura, S., *et al.* Differences in perception of everyday odors: a
563 Japanese-German cross-cultural study. *Chem. Senses* **23**, 31-38 (1998).
- 564 5. Amoore, J.E. Specific anosmia and the concept of primary odors. in *Chemical*
565 *Senses and Flavor 2* 267-281 (D. Reidel Publishing Company, Dordrecht-Holland,
566 1977).
- 567 6. Menashe, I., *et al.* Genetic elucidation of human hyperosmia to isovaleric acid.
568 *PLoS Biol.* **5**, e284 (2007).
- 569 7. McRae, J.F., *et al.* Genetic Variation in the Odorant Receptor OR2J3 Is
570 Associated with the Ability to Detect the "Grassy" Smelling Odor, cis-3-hexen-1-ol.
571 *Chem. Senses* **37**, 585-593 (2012).
- 572 8. Jaeger, S.R., *et al.* A Mendelian Trait for Olfactory Sensitivity Affects Odor
573 Experience and Food Selection. *Curr. Biol.* **23**, 1601-1605 (2013).
- 574 9. Keller, A., Zhuang, H., Chi, Q., Vosshall, L.B. & Matsunami, H. Genetic variation
575 in a human odorant receptor alters odour perception. *Nature* **449**, 468-472 (2007).
- 576 10. Wetzel, C.H., *et al.* Specificity and sensitivity of a human olfactory receptor
577 functionally expressed in human embryonic kidney 293 cells and *Xenopus Laevis*
578 oocytes. *J. Neurosci.* **19**, 7426-7433 (1999).
- 579 11. Spehr, M., *et al.* Identification of a testicular odorant receptor mediating human
580 sperm chemotaxis. *Science* **299**, 2054-2058 (2003).
- 581 12. Sanz, G., Schlegel, C., Pernellet, J.C. & Briand, L. Comparison of odorant
582 specificity of two human olfactory receptors from different phylogenetic classes and
583 evidence for antagonism. *Chem. Senses* **30**, 69-80 (2005).
- 584 13. Matarazzo, V., *et al.* Functional characterization of two human olfactory receptors
585 expressed in the baculovirus Sf9 insect cell system. *Chem. Senses* **30**, 195-207 (2005).
- 586 14. Jacquier, V., Pick, H. & Vogel, H. Characterization of an extended receptive
587 ligand repertoire of the human olfactory receptor OR17-40 comprising structurally related
588 compounds. *J. Neurochem.* **97**, 537-544 (2006).
- 589 15. Neuhaus, E.M., Mashukova, A., Zhang, W., Barbour, J. & Hatt, H. A specific heat
590 shock protein enhances the expression of mammalian olfactory receptor proteins. *Chem.*
591 *Senses* **31**, 445-452 (2006).
- 592 16. Schmiedeberg, K., *et al.* Structural determinants of odorant recognition by the
593 human olfactory receptors OR1A1 and OR1A2. *J. Struct. Biol.* **159**, 400-412 (2007).
- 594 17. Saito, H., Chi, Q., Zhuang, H., Matsunami, H. & Mainland, J.D. Odor coding by a
595 Mammalian receptor repertoire. *Sci. Signal.* **2**, ra9 (2009).
- 596 18. Saito, H., Kubota, M., Roberts, R.W., Chi, Q. & Matsunami, H. RTP family
597 members induce functional expression of mammalian odorant receptors. *Cell* **119**, 679-
598 691 (2004).
- 599 19. Keller, A., Hempstead, M., Gomez, I.A., Gilbert, A.N. & Vosshall, L.B. An
600 olfactory demography of a diverse metropolitan population. *BMC Neurosci.* **13**, 122
601 (2012).
- 602 20. Zhuang, H. & Matsunami, H. Evaluating cell-surface expression and measuring
603 activation of mammalian odorant receptors in heterologous cells. *Nat. Protoc.* **3**, 1402-
604 1413 (2008).

- 605 21. Hayden, S., *et al.* Ecological adaptation determines functional mammalian
606 olfactory subgenomes. *Genome Res.* **20**, 1-9 (2010).
- 607 22. The 1000 Genomes Project Consortium. A map of human genome variation from
608 population-scale sequencing. *Nature* **467**, 1061-1073 (2010).
- 609 23. McRae, J.F., *et al.* Identification of Regions Associated with Variation in
610 Sensitivity to Food- Related Odors in the Human Genome. *Curr. Biol.* **23**, 1596-1600
611 (2013).
- 612 24. Eriksson, N., *et al.* Web-based, participant-driven studies yield novel genetic
613 associations for common traits. *PLoS Genet.* **6**, e1000993 (2010).
- 614 25. Eriksson, N., *et al.* A genetic variant near olfactory receptor genes influences
615 cilantro preference. *arXiv arXiv:1209.2096 [q-bio.GN]* (2012).
- 616 26. Zhang, X., *et al.* Characterizing the expression of the human olfactory receptor
617 gene family using a novel DNA microarray. *Genome Biol.* **8**, R86 (2007).
- 618 27. Fushan, A.A., Simons, C.T., Slack, J.P., Manichaikul, A. & Drayna, D. Allelic
619 Polymorphism within the TAS1R3 Promoter is Associated with Human Taste Sensitivity
620 to Sucrose. *Curr. Biol.* (2009).
- 621 28. Waszak, S.M., *et al.* Systematic inference of copy-number genotypes from
622 personal genome sequencing data reveals extensive olfactory receptor gene content
623 diversity. *PLoS Comput. Biol.* **6**, e1000988 (2010).
- 624 29. Nozawa, M., Kawahara, Y. & Nei, M. Genomic drift and copy number variation of
625 sensory receptor genes in humans. *Proc. Natl. Acad. Sci. U. S. A.* **104**, 20421-20426
626 (2007).
- 627 30. Grantham, R. Amino acid difference formula to help explain protein evolution.
628 *Science* **185**, 862-864 (1974).
- 629 31. Laird, D.W. & Molday, R.S. Evidence against the role of rhodopsin in rod outer
630 segment binding to RPE cells. *Invest. Ophthalmol. Vis. Sci.* **29**, 419-428 (1988).
- 631 32. Zhuang, H. & Matsunami, H. Synergism of accessory factors in functional
632 expression of mammalian odorant receptors. *J. Biol. Chem.* **282**, 15284-15293 (2007).
- 633 33. Li, Y.R. & Matsunami, H. Activation state of the m3 muscarinic acetylcholine
634 receptor modulates mammalian odorant receptor signaling. *Sci. Signal.* **4**, ra1 (2011).
- 635 34. Li, H. Tabix: fast retrieval of sequence features from generic TAB-delimited files.
636 *Bioinformatics* **27**, 718-719 (2011).
- 637 35. Chelala, C., Khan, A. & Lemoine, N.R. SNPnexus: a web database for functional
638 annotation of newly discovered and public domain single nucleotide polymorphisms.
639 *Bioinformatics* **25**, 655-661 (2009).

640
641

642

Figure 1




Figure 2




Figure 3




Figure 4





Figure 5







Figure 6